Emricasan (Standard)

[1]Barreyro FJ, et al. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 2015 Mar;35 (3) :953-66.|[2]Hoglen NC, et al. Characterization of IDN-6556 (3-[2- (2-tert-butyl-phenylaminooxalyl) -amino]-propionylamino]-4-oxo-5- (2,3,5,6-te trafluoro-phenoxy) -pentanoic acid) : a liver-targeted caspase inhibitor. J Pharmacol Exp Ther. 2004 May;309 (2) :634-40.|[3]McCall M, et al. The caspase inhibitor IDN-6556 (PF3491390) improves marginal mass engraftment after islet transplantation in mice. Surgery. 2011 Jul;150 (1) :48-55.|[4]Tian J, et al. Combination of Emricasan with AP24534 Synergistically Reduces Ischemia/Reperfusion Injury in Rat Brain Through Simultaneous Prevention of Apoptosis and Necroptosis. Transl Stroke Res. 2017 Nov 4.|[5]Gracia-Sancho J, et al. Emricasan Ameliorates Portal Hypertension and Liver Fibrosis in Cirrhotic Rats Through a Hepatocyte-Mediated Paracrine Mechanism. Hepatol Commun. 2019 Apr 22;3 (7) :987-1000.|[6]Xu M, et al. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nat Med. 2016 Oct;22 (10) :1101-1107.